- Home
- HYFM vs CVKD Comparison
HYFM vs CVKD Comparison
Compare HYFM & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- CVKD
- Stock Information
- Founded
- HYFM 1977
- CVKD 2022
- Country
- HYFM United States
- CVKD United States
- Employees
- HYFM N/A
- CVKD N/A
- Industry
- HYFM Industrial Machinery/Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HYFM Industrials
- CVKD Health Care
- Exchange
- HYFM Nasdaq
- CVKD Nasdaq
- Market Cap
- HYFM 31.3M
- CVKD 26.3M
- IPO Year
- HYFM 2020
- CVKD 2023
- Fundamental
- Price
- HYFM $0.55
- CVKD $17.04
- Analyst Decision
- HYFM Hold
- CVKD Strong Buy
- Analyst Count
- HYFM 2
- CVKD 2
- Target Price
- HYFM $0.70
- CVKD $46.00
- AVG Volume (30 Days)
- HYFM 105.8K
- CVKD 85.6K
- Earning Date
- HYFM 11-07-2024
- CVKD 11-07-2024
- Dividend Yield
- HYFM N/A
- CVKD N/A
- EPS Growth
- HYFM N/A
- CVKD N/A
- EPS
- HYFM N/A
- CVKD N/A
- Revenue
- HYFM $200,158,000.00
- CVKD N/A
- Revenue This Year
- HYFM N/A
- CVKD N/A
- Revenue Next Year
- HYFM $3.48
- CVKD N/A
- P/E Ratio
- HYFM N/A
- CVKD N/A
- Revenue Growth
- HYFM N/A
- CVKD N/A
- 52 Week Low
- HYFM $0.43
- CVKD $5.40
- 52 Week High
- HYFM $1.20
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- HYFM 28.99
- CVKD 57.77
- Support Level
- HYFM $0.55
- CVKD $16.25
- Resistance Level
- HYFM $0.62
- CVKD $19.97
- Average True Range (ATR)
- HYFM 0.05
- CVKD 1.80
- MACD
- HYFM -0.01
- CVKD -0.04
- Stochastic Oscillator
- HYFM 0.06
- CVKD 54.70
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.